FDA Adverse Event Injury Summary report: N

EVIS COLONOVIDEOSCOPE

MDR report key: 14595239 · Received June 3, 2022

Report

Report Number
8010047-2022-09393
Event Type
Injury
Date Received
June 3, 2022
Date of Event
June 28, 2021
Report Date
July 6, 2022
Manufacturer
OLYMPUS MEDICAL SYSTEMS CORP.
Product Code
FDF
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
JA
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

THE DEVICE REFERENCED IN THIS REPORT HAS NOT BEEN RETURNED TO OLYMPUS FOR EVALUATION. THE INVESTIGATION IS ONGOING. THIS REPORT WILL BE UPDATED UPON COMPLETION OF THE INVESTIGATION OR UPON RECEIPT OF ADDITIONAL RELEVANT INFORMATION.

Additional Manufacturer Narrative · 0

THIS REPORT IS BEING SUPPLEMENTED TO PROVIDE ADDITIONAL INFORMATION BASED ON THE LEGAL MANUFACTURER'S FINAL INVESTIGATION. THE DEVICE HISTORY RECORD WAS UNABLE TO BE REVIEWED FOR THIS DEVICE SINCE THE LOT NUMBER WAS NOT PROVIDED. HOWEVER, OLYMPUS ONLY RELEASES PRODUCTS TO MARKET THAT MEET ALL MANUFACTURING SPECIFICATIONS AND FINAL PRODUCT RELEASE CRITERIA. BASED ON THE RESULTS OF THE INVESTIGATION, THE RELATIONSHIP BETWEEN THE DEVICE AND THE ADVERSE EVENT CANNOT BE CONFIRMED. THERE WAS NO COMPLAINT REPORTED ON THE SUBJECT DEVICE. THERE IS NO EVIDENCE OF AN OLYMPUS DEVICE MALFUNCTION. OLYMPUS WILL CONTINUE TO MONITOR FIELD PERFORMANCE FOR THIS DEVICE.

Description of Event or Problem · 0

IT IS REPORTED IN THE LITERATURE ARTICLE TITLED:¿ LONG-TERM OUTCOMES OF ENDOSCOPIC BALLOON DILATION FOR INTESTINAL STRICTURES IN PATIENTS WITH CROHN¿S DISEASE DURING MAINTENANCE TREATMENT WITH ANTI-TUMOR NECROSIS FACTOR ALPHA ANTIBODIES,¿ PATIENT EXPERIENCED ADVERSE EVENTS DURING AND AFTER PROCEDURES USING OLYMPUS DEVICES. CASE WITH PATIENT IDENTIFIER (B)(6) REPORTS PCF-P240AI. CASE WITH PATIENT IDENTIFIER (B)(6) REPORTS PCF-Q260AI. STUDY BACKGROUND AND AIM: EFFICACY OF ENDOSCOPIC BALLOON DILATION (EBD) FOR INTESTINAL STRICTURES IN PATIENTS WITH CROHN¿S DISEASE (CD) RECEIVING ANTI-TUMOR NECROSIS FACTOR ALPHA ANTI BODIES (ANTI-TNF) AS MAINTENANCE THERAPY IS UNCLEAR. WE INVESTIGATED THE LONG-TERM EFFICACY AND SAFETY OF EBD FOR INTESTINAL STRICTURES IN PATIENTS WITH CD RECEIVING ANTI-TNF. METHODS: RETROSPECTIVE DATA ANALYSIS FROM PATIENTS WITH CD WHO RECEIVED ANTI-TNF AS MAINTENANCE THERAPY FROM 2008 TO 2017, UNDERWENT EBD, AND WERE FOLLOWED UP FOR =6 MONTHS. THE PRIMARY ENDPOINT WAS THE CUMULATIVE SURGERY-FREE RATE. THE MAIN SECONDARY ENDPOINTS WERE TECHNICAL SUCCESS, REPEAT EBD RATE, RISK FACTORS AFFECTING SURGICAL OUTCOMES, AND SAFETY. RESULTS: SEVENTY-TWO PATIENTS WITH CD WERE ASSESSED. THE MEDIAN OBSERVATION PERIOD AFTER EBD WAS 50 MONTHS. THE TECHNICAL SUCCESS RATE WAS 67%. THE 3- AND 5-YEAR CUMULATIVE SURGERY-FREE RATES WERE 81.1% AND 73.5%, RESPECTIVELY. THE REPEAT EBD RATE WAS 74%. MULTIVARIABLE ANALYSES SHOWED THAT RISK FACTORS AFFECTING SURGICAL OUTCOMES WERE AGE AT DISEASE ONSET =16 YEARS (HAZARD RATIO 3.69; 95% CONFIDENCE INTERVAL 1.36¿10.01; P = 0.011). SERIOUS COMPLICATIONS REQUIRING SURGERY DEVELOPED IN THREE PATIENTS. CONCLUSIONS: ENDOSCOPIC BALLOON DILATION WAS AN EFFECTIVE AND SAFE SHORT-TERM TREATMENT AND A USEFUL LONG-TERM TREATMENT FOR CD PATIENTS WITH INTESTINAL STRICTURES RECEIVING ANTI-TNF AS MAINTENANCE THERAPY. THE ONLY SERIOUS COMPLICATION OBSERVED WAS PERFORATION IN THREE PATIENTS; HOWEVER, THEY UNDERWENT SURGERY AND RECOVERED. PERFORATION WAS OBSERVED IN 3/72 (4.2%) PATIENTS AND IN 3/290 (1.0%) ENDOSCOPIC PROCEDURES. PERFORATION DURING EBD OCCURRED ONLY IN ONE PATIENT. PERFORATION DURING INSERTION OCCURRED IN TWO PATIENTS, BOTH OF WHICH WERE IN THE AFFECTED REGION OF THE ILEUM WITH A LONGITUDINAL ULCER. BLEEDING REQUIRING TRANSFUSION OR SERIOUS COMPLICATIONS REQUIRING LONG-TERM HOSPITALIZATION WERE NOT NOTED. THERE IS NO REPORT OF ANY OLYMPUS DEVICE MALFUNCTION REPORTED IN ANY PROCEDURE DESCRIBED IN THIS LITERATURE.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1801574 EVIS COLONOVIDEOSCOPE COLONOVIDEOSCOPE FDF OLYMPUS MEDICAL SYSTEMS CORP. PCF-P240AI

Patients

Seq Age Sex Outcome Treatment
1 Unknown Other| R